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AIM
The overall aim of the project was to create a clinical practice
guideline with recommendations for GN, using an evidence-
based approach. After topics and relevant clinical questions
were identified, the pertinent scientific literature on those
topics was systematically searched and summarized.
OVERVIEW OF PROCESS
The development of the guideline included sequential and
concurrent steps:
K Appoint the Work Group and Evidence Review Team
(ERT), which were responsible for different aspects of the
process.
K Confer to discuss process, methods, and results.
K Develop and refine topics.
K Assign topics to systematic review or narrative review.
K Define specific populations, interventions or predictors,
and outcomes of interest for systematic review topics.
K Create and standardize quality assessment methods.
K Create data-extraction forms.
K Develop literature search strategies and run searches.
K Screen abstracts and retrieve full articles based on
predetermined eligibility criteria.
K Extract data and perform critical appraisal of the
literature.
K Incorporate existing systematic reviews and underlying
studies.
K Grade quality of the outcomes of each study.
K Tabulate data from articles into summary tables.
K Update the systematic review search.
K Grade the quality of evidence for each outcome, and
assess the overall quality and findings of bodies of
evidence with the aid of evidence profiles.
K Write recommendations and supporting rationale state-
ments.
K Grade the strength of the recommendations based on the
quality of the evidence and other considerations.
The Work Group, KDIGO Co-Chairs, ERT, and NKF
support staff met for three 3-day meetings for training in the
guideline development process, topic discussion, and con-
sensus development.
Creation of Groups
The KDIGO Co-Chairs appointed the Co-Chairs of the Work
Group, who then assembled the Work Group to be
responsible for the development of the guidelines. The Work
Group included individuals with expertise in adult and
pediatric nephrology, epidemiology, and kidney pathology.
For support in evidence review, expertise in methods, and
guideline development, the NKF contracted with the ERT
based at the Tufts Center for Kidney Disease Guideline
Development and Implementation at Tufts Medical Center in
Boston, Massachusetts, USA. The ERT consisted of physi-
cian-methodologists with expertise in nephrology and
internal medicine, and research associates and assistants.
The ERT instructed and advised Work Group members in all
steps of literature review, critical literature appraisal, and
guideline development. The Work Group and the ERT
collaborated closely throughout the project.
Systematic Review: General Process
The first task of the Work Group was to define the overall
topics and goals for the guideline. The Work Group
Co-Chairs drafted a preliminary list of topics. The Work
Group identified the key clinical questions and triaged topics
for systematic review and narrative review. The Work Group
and ERT further developed and refined each systematic
review topic, specified screening criteria, literature search
strategies, and data extraction forms.
The ERT performed literature searches, and conducted
abstract and article screening. The ERT also coordinated
the methodological and analytic processes of the report. In
addition, it defined and standardized the methodology in
relation to these searches and data extraction, and produced
summaries of the evidence. Throughout the project, the ERT
offered suggestions for guideline development, led discus-
sions on systematic review, literature searches, data extrac-
tion, assessment of quality and applicability of articles,
evidence synthesis, grading of evidence and recommenda-
tions, and consensus development. With input from the
Work Group, the ERT finalized eligible studies, performed
all data extraction, and summarized data into summary
tables. They also created preliminary evidence profiles
(described below), which were completed by the Work
Group members. The Work Group members reviewed all
included articles, data extraction forms, and summary tables
for accuracy and completeness. The Work Group took the
primary role of writing the recommendations and rationale
statements, and retained final responsibility for the content
of the recommendation statements and the accompanying
narrative.
For questions of treatments in GN, systematic reviews of
the eligible RCTs were undertaken (Table 32). For these
topics, the ERT created detailed data-extraction forms and
extracted information on baseline data for the populations,
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Table 32 | Screening criteria for systematic review topics of nontreatment and treatment
PICOD criteria
Chapter 3: SSNS in Children
Population Steroid sensitive (Any definition), Children, biopsy not required, Define Nephrotic Syndrome: Urine Prot:Cr Ratio & Serum
albumin
Intervention Long course or alternate day prednisone
Comparator Short course or daily prednisone
Outcomes Proteinuria, Complete Remission, Relapse
Study design RCTs; No minimum follow-up
Minimum N of Subjects No minimum N
FRNS in Children
Population Steroid resistance, Children, biopsy not required, Define Nephrotic Syndrome: Urine Prot:Cr Ratio & Serum albumin
Intervention Cyclosporine, Cytoxan, Chlorambucil, Tacrolimus (Prograf), Rituximab, MMF, Levamisole, Plasmapheresis, Mizoribine, AZA
Comparator Prednisone and other comparators depending on the study
Outcomes Proteinuria, Complete Remission, Relapse
Study design RCTs
No minimum follow-up
Nonrandomized comparative studies
Retrospective comparative or prospective or retrospective single arm cohort
Minimum duration: 6 months
Minimum N of Subjects No minimum N
SDNS in Children
Population Steroid resistance, Children, biopsy not required, Define Nephrotic Syndrome: Urine Prot:Cr Ratio & Serum albumin
Intervention Cyclosporine, Cytoxan, Chlorambucil, Tacrolimus (Prograf), Rituximab, MMF, Levamisole, Plasmapheresis, Mizoribine, AZA
Comparator Prednisone and other comparators depending on the study
Outcomes Proteinuria, Complete Remission, Relapse
Study design RCTs
No minimum follow-up
Nonrandomized comparative studies
Retrospective comparative or prospective or retrospective single arm cohort
Minimum duration: 6 months
Minimum N of Subjects No minimum N
Chapter 4: SRNS in Children
Population Steroid resistance (define), Children, biopsy not required, Define Nephrotic Syndrome: Urine Prot:Cr Ratio & Serum albumin
Intervention Cyclosporine, Cytoxan, Chlorambucil, Tacrolimus (Prograf), Rituximab, MMF, Levamisole, Plasmapheresis, Mizoribine, AZA
Comparator Prednisone, other comparators depending on the study
Outcomes Proteinuria, Complete Remission, Relapse
Study design RCTs
No minimum follow-up
Nonrandomized comparative studies
Retrospective comparative or prospective or retrospective single arm cohort
Minimum duration: 6 months
Minimum N of Subjects No minimum N
Chapter 5: MCD in Adults (biopsy proven)
Population Minimal Change Disease, biopsy-proven, Define Nephrotic Syndrome: Urine Prot:Cr Ratio & Serum albumin
Intervention Short course prednisone and Long course prednisone and Cyclosporine, Cytoxan, Chlorambucil, Tacrolimus (Prograf),
Rituximab, MMF, Levamisole, Plasmapharesis, Mizoribine, AZA
Comparator No treatment, Short course prednisone, Prednisone and other comparators depending on study
Outcomes Change in Proteinuria, Complete Remission, Partial Remission, Relapse, GFR, SCr doubling, ESRD, Death
Study design RCTs
No minimum follow-up
Nonrandomized comparative studies
Retrospective comparative or prospective or retrospective single arm cohort
Minimum duration: 6 months
Minimum N of Subjects NX10/arm
Table 32 continued on following page
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Table 32 | Continued
PICOD criteria
Chapter 6: FSGS in Adults
Population Population FSGS, by biopsy and list FSGS subtypes, Adults, Define Nephrotic Syndrome: Urine Prot:Cr Ratio & Serum albumin
Intervention Long course prednisone, Cyclosporine +/ACE-I, MMF +/ ACE-I, Prograf +/ ACE-I, Rituximab +/ ACE-I, Lamivudine +/
ACE-I, Plasmapheresis +/ ACE-I-levamisole, Mizoribine, AZA
Comparator Any treatment
Outcomes Change in Proteinuria, Complete Remission, Partial Remission, Relapse, GFR, SCr doubling, ESRD, Death
Study design RCTs
No minimum follow-up
Nonrandomized comparative studies
Retrospective comparative or prospective or retrospective single arm cohort
Minimum duration: 6 mo
Minimum N of Subjects N X10/arm
Chapter 7: MN
Population Biopsy-proven MN
Intervention Steroids alone (any regimen), Alkylating agent (Cyclophosphamide or Chlorambucil), CNI (Cyclosporine or Tacrolimus +/
steroids), IVIG, ACE-I or ARBs (+/steroids), AZA or Mizoribine (+/ steroids), Alkylating agent, MMF (+/ steroids), ACTH,
Rituximab, Eculizumab, Sirolimus, Pentoxyphlline, any combination
Comparator Steroids, No treatment, ACE-I or ARBs, Calcineurin inhibitor (Tac, CsA), Alkylating agents
CNI, steroids only, no treatment, any combination, any other treatment
Outcomes All cause mortality, ESRD, CKD 5, RRT, etc., Progression of CKD, SCr increase/GFR decrease, Change in CKD stage, Disease
remission, Partial disease remission, Protocol-driven additional treatment of GN, Disease relapse, Quality of life, Proteinuria,
Adverse Events: Including cancer, thromboembolic complications, pulmonary embolism, CVD especially acute MI
Study design RCTs; Minimum duration X6 months for remissions/AE, 5 years for survival
Minimum N of Subjects N X10/arm
Chapter 8: MPGN
Population Biopsy-proven MPGN
Intervention Rituximab, Eculizumab, CNI (CsA, Tac), MMF, Sirolimus, ACE-I & ARBs, Pentoxyphylline, IVIG, Treatment of relapse (any), Steroid
therapy (any regimen)
Comparator Any
Outcomes Complete & partial remission, Relapse, Categorical changes in proteinuria, Categorical changes in kidney function (Cr, GFR),
ESRD, Death/survival, Adverse events
Study design RCTs
Minimum follow-up 6 mo
Nonrandomized comparative studies
Prospective or retrospective
Minimum duration: 12 mo
Minimum N of Subjects N X20
Chapter 9: Infection-Related MN
Population Patients with infection associated GN, biopsy-proven, Postinfectious GN
Intervention Antiviral (lamuvidine, ribavirin or interferon) for HBV, HCV, Anti-parasitic agents for malaria or other helminthic/protozoal
infections. For post infectious GN: any intervention
Comparator Any treatment
Outcomes All cause mortality, ESRD, CKD 5, RRT, etc., Progression of CKD, SCr increase/GFR decrease, Change in CKD stage, Disease
remission, Partial disease remission, Protocol-driven additional treatment of GN, Disease relapse, Quality of life, Proteinuria, AE:
Including cancer, thromboembolic complications, pulmonary embolism, CVD especially acute MI
Study design RCTs; No minimum duration of follow-up
Minimum N of Subjects For post-infectious: N X10 for RCTs, N X20 for observational
Chapter 10: IgAN
Population Biopsy-proven IgAN, Primary disease only (exclude secondary disease)
Intervention Any
Comparator Any, regardless of ACE-I use, BP control, etc.
Outcomes All cause mortality, ESRD, CKD 5, RRT, etc., Progression of CKD, SCr increase/GFR decrease, Change in CKD stage, Disease
remission, Protocol-driven additional treatment of GN, Disease relapse, Proteinuria
Study design RCTs; Minimum follow-up: 6 months
Minimum N of Subjects N X10
Table 32 continued on following page
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Table 32 | Continued
PICOD criteria
Chapter 11: HSP Nephritis
Population Biopsy-proven HSP
Intervention Any (for RCTs and nonrandomized comparative studies)
Comparator Any (for RCTs and nonrandomized comparative studies)
Outcomes All cause mortality, ESRD, CKD 5, RRT, etc., Progression of CKD, SCr increase/GFR decrease, Change in CKD stage, Disease
remission, Protocol-driven additional treatment of GN, Disease relapse, Proteinuria
Study design RCTs and nonrandomized comparative studies
Minimum N of Subjects N X10
Chapter 12: LN Induction Therapy
Population Biopsy-proven Lupus nephritis, class III, IV , V, (also any combination of class V + III or V + IV ), Adults and pediatric
Intervention MMF, Cyclophosphamide, Rituximab, Long duration Cyclophosphamide, i.v. cyclophosphamide, Cyclosporine/Tacrolimus +
MMF + Prednisone
Hydroxychloroquine (class V) as a concomitant therapy with other drug therapies
Comparator Cyclophosphamide (p.o. or i.v.), Azathioprine, Cyclophosphamide, EURO protocol cyclophosphamide, p.o. cyclophosphamide,
Cyclophosphamide. No addition of hydroxychloroquine
Outcomes Mortality, Need for RRT/ renal survival, Proteinuria, Kidney function preservation in terms of SCr/eGFR such as doubling of SCr
— as categorical outcome, Remission and Relapse, Preservation of menses (fertility), Thrombotic and thromboembolic events,
Alopecia and other adverse events
Study design RCTs
Minimum follow-up: 6 months
Nonrandomized comparative studies
Prospective study design
Minimum follow-up: 6 months
Minimum N of Subjects N X10/arm for RCTs and N X30 for nonrandomized comparative studies
Chapter 12: LN Maintenance Therapy
Population Biopsy-proven Lupus nephritis, class III, IV, V, (also any combination of class V+III or V+IV), Both adults and pediatric
Intervention RCTs:
Maintenance therapy 1. MMF, 2. MMF, 3. Steroids, Hydroxychloroquine
Nonrandomized comparative studies:
Etanercept, TNF alpha antagonists (e.g., infliximab, etc), CTLA4-Ig and derivatives, Campath, Abetimus (LJP394)
Comparator Cyclophosphamide, Azathioprine, Placebo/ No Rx
Outcomes Mortality, Need for RRT/ renal survival, Proteinuria, Kidney function preservation in terms of SCr/eGFR such as doubling of
SCr — as categorical outcome, Remission and Relapse, Preservation of menses (fertility), Thrombotic and thromboembolic
events, Alopecia and other adverse events
Study design RCTs
Minimum follow-up: 12 months
Nonrandomized comparative studies
Prospective study design
Minimum follow-up: 12 months
Minimum N of Subjects N X10/arm for RCTs and N X30 for nonrandomized comparative studies
Chapter 13: Treatment of Pauci-immune Focal and Segmental Necrotizing GN
Population Adults or pediatric population, ANCA Vasculitis, biopsy-proven, Positive ANCA, Wegener’s granulomatosis, microscopic
polyangiitis, pauci-immune GN). Churg Strauss syndrome
Intervention RCTs:
Cyclophosphamide+steroids, Cyclophosphamide+steroids+Plasmapheresis/IVIG, MMF, i.v. cyclophosphamide regimens,
Pulsed cyclophosphamide, Rituximab
Maintenance:
Azathioprine, MMF, Cyclophosphamide, Methotrexate, Cyclosporine, Leflunomide
For nonrandomized comparative studies:
MMF, Rituximab, Infliximab, Campath, Abetacept, Cyclosporine, IVIG, Leflunomide
Plasmapheresis or immunoadsorption
Comparator Cyclophosphamide, Cyclophosphamide+steroids, Cyclophosphamide, p.o. cyclophosphamide regimens, Continuous p.o.
cyclophosphamide
Maintenance:
Any comparator
Outcomes Mortality, Kidney survival, Relapse, Disease free survival, Thromboembolism, Proteinuria
Coming off dialysis
Study design RCTs:
Minimum follow-up: 6 months; For maintenance therapy trials, duration at least 1 year
Nonrandomized comparative studies:
Prospective or Retrospective study design
Minimum follow-up: 6 months
Minimum N of Subjects Any N for RCTs and NX30 for nonrandomized comparative studies
Table 32 continued on following page
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interventions, study design, results, and provided an assess-
ment of quality of study and outcomes. The ERT then
tabulated studies in summary tables, and assigned grades for
the quality of the evidence in consultation with the Work
Group.
Refinement of Topics
At the first 3-day meeting, Work Group members added
comments to the scope-of-work document as prepared by the
Work Group Chairs and ERT, until the initial working
document included all topics of interest to the Work Group.
The inclusive, combined set of questions formed the basis for
the deliberation and discussion that followed. The Work
Group aimed to ensure that all topics deemed clinically
relevant and worthy of review were identified and addressed.
The major topic areas of interest for the care of GN included
IgAN, lupus and vasculitis, MCD and FSGS, and MN,
MPGN, and infection.
At the initiation of the guideline development process, it
was agreed that these guidelines would focus on patients who
have GN. Thus, all topics, systematic reviews, and study
eligibility criteria were restricted to patients with a biopsy-
proven diagnosis of GN, with exceptions for diseases that do
not require biopsy confirmation.
Based on the list of topics, the Work Group and ERT
developed a list of specific research questions for
which systematic review would be performed. For each
systematic review topic, the Work Group Co-Chairs and the
ERT formulated well-defined systematic review research
questions using a well-established system.758 For each
question, explicit criteria were agreed on for the population,
intervention or predictor, comparator, outcomes of interest,
and study design features. A list of outcomes of interest was
generated.
The Work Group and the ERT agreed upon specific
outcomes of interest: all-cause mortality, ESRD, disease
remission, relapse, proteinuria, kidney function, and adverse
events. ESRD and mortality were ranked as being of critical
importance. The Work Group ranked patient-centered
clinical outcomes (such as death, ESRD, remission and
categorical proteinuria and kidney function changes) as
more important than intermediate outcomes (such as
continuous outcomes of proteinuria and kidney function).
Categorical outcomes are those that describe when a
patient moves from one health state (e.g., macroalbuminuria)
to another (e.g., no albuminuria). Continuous outcomes
would be evaluations of the laboratory values alone (e.g.,
change in proteinuria in mg/dl). The outcomes were
further categorized as being of critical, high, or moderate
clinical importance to patients with GN. The specific criteria
used for each topic are described below in the description
of the review topics. In general, eligibility criteria were
determined based on clinical value, relevance to the guide-
lines and clinical practice, determination whether a set of
studies would affect recommendations or the strength of
evidence, and practical issues, such as available time and
resources.
Literature Searches and Article Selection
Searches were conducted in MEDLINE and Cochrane
through January 20, 2011. All searches were also supple-
mented by articles identified by Work Group members
through November 2011. For detailed search strategies, please
see Online Appendix 1.
Search results were screened by the ERT for rele-
vance using predefined eligibility criteria, described
below. For questions related to treatment, the systematic
search aimed to identify RCTs as described in Table 32.
For some topics, nonrandomized comparative trials were also
reviewed, in addition to RCTs, to strengthen the evidence
base.
For most topics, the minimum sample size was 410. For
MCD and FSGS, because of sparse data, smaller studies were
included.
Table 32 | Continued
PICOD criteria
Chapter 14: Treatment of Anti-GBM GN
Population Anti-GBM disease, biopsy-proven, Anti-GBM antibody, Adults or pediatric population
Either renal or combined pulmonary renal involvement
Intervention Prednisone+Cyclophosphamideþ Plasmapheresis, Prednisoneþ cyclophosphamide+Immunoadsorption
Comparator PrednisoneþCyclophosphamide, Prednisone+Cyclophosphamide
Outcomes Mortality, Recovery of kidney function, Proteinuria
Study design Any; No minimum follow-up
Minimum no. of
Subjects
No minimum N
ACE-I, angiotensin-converting enzyme inhibitors; ACTH, adrenocorticotropic hormone; AE, adverse events; ANCA, anti-neutrophil cytoplasmic antibody; ARB, angiotensin-
receptor blocker; AZA, azathioprine; BP, blood pressure; CKD, chronic kidney disease; CNI, calcineurin inhibitors; Cr, creatinine; CsA, cyclosporine; CTLA 4-lg, CTLA-4 Ig fusion
protein; CVD, cardiovascular disease; Cyc, cyclophosphamide; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FRNS, frequently relapsing nephrotic
syndrome; FSGS, focal segmental glomerulonephritis, GFR, glomerular filtration rate; GN, glomerulonephritis; HBV, hepatitis B virus; HCV, hepatitis C virus; HSP, Henoch-
Scho¨nlein purpura; IgAN, immunoglobulin A nephropathy; i.v., intravenous; IVIG, intravenous immunoglobulin; LN, lupus nephritis; MCD, minimal-change disease; MI,
myocardial infarction; MMF, mycophenolate mofetil; MN, membranous nephropathy; mo, month; MPGN, membranoproliferative glomerulonephritis; N, number; PICOD,
population, intervention, comparison, outcomes, design (study); p.o., oral; Prot, proteinuria; RCT, randomized controlled trials; RRT, renal replacement therapy; Rx, treatment;
SCr, serum creatinine; SDNS, steroid-dependent nephrotic syndrome; SRNS, steroid-resistant nephrotic syndrome; SSNS; steroid-sensitive nephrotic syndrome; Tac, tacrolimus.
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For most topics, the minimum duration of follow-up of
6 months was chosen based on clinical reasoning. For the
treatments of interest, the proposed effects on patient-
important clinical outcomes require long-term exposure and,
typically, would not be expected to become evident before
several months of follow-up.
In addition, a search was conducted for data on predictors
of kidney failure, kidney function, and remission. Only
associations from multivariable regression analyses were
considered. These ‘‘predictor studies’’ were not graded for
quality. For these topics, the ERT completed its search in
October 5, 2009 and did not update the search.
Included were studies of all patients with glomerular
diseases, excluding those with diabetic nephropathy, throm-
botic microangiopathy, amyloidosis, Alport’s and other
hereditary glomerular diseases, paraproteinemia, and recur-
rence of GN following kidney transplantation.
Interventions of interest included all treatments for GN,
including drugs, herbs, dietary supplements, tonsillectomy,
infection prophylaxis, and postdiagnosis tests to determine
treatment.
A list of pertinent, published systematic reviews relevant
to GN guidelines was generated, organized by topic, and
reviewed with the Work Group. If an existing systematic
review adequately addressed a question of interest as
determined by the Work Group, this was used instead of a
de novo systematic review by the ERT. These systematic
reviews were then used as the starting points for building the
evidence base and supplemented with articles from the ERT’s
own searches. If these reviews were deemed to adequately
address topics of interest (even if only selected outcomes were
reviewed), de novo searches on these topics were limited to
the time period since the end of literature search within the
systematic reviews.
Editorials, letters, stand-alone abstracts, unpublished
reports, and articles published in non–peer-reviewed journals
were excluded. The Work Group also decided to exclude
publications from journal supplements.
Literature yield for systematic review topics. Table 33
summarizes the numbers of abstracts screened, articles
retrieved, studies data extracted, and studies included in
summary tables.
Data extraction. The ERT designed data-extraction forms
to tabulate information on various aspects of the primary
studies. Data fields for all topics included study setting,
patient demographics, eligibility criteria, type of GN,
numbers of subjects randomized, study design, study funding
source, descriptions of interventions (or predictors), descrip-
tion of outcomes, statistical methods used, results, quality of
outcomes (as described below), limitations to general-
izability, and free-text fields for comments and assessment
of biases.
Summary tables
Summary tables were developed to tabulate the data from
studies pertinent to each question of intervention. Each
summary table contains a brief description of the outcome,
baseline characteristics of the population, intervention,
comparator results, and methodological quality of each
outcome. Baseline characteristics include a description of
the study size, country of residence, and baseline kidney
function and proteinuria. Intervention and concomitant
therapies, and the results, were all captured. The studies were
listed by outcome within the table, based on the hierarchy of
important outcomes (Table 34). Categorical and continuous
outcomes were summarized in separate sets of tables. Work
Group members were asked to proof all data in summary tables
on RCTs and non-RCTs. Separate sets of summary tables
were created for predictor studies. Summary tables are available
at www.kdigo.org/clinical_practice_guidelines/GN.php.
Evaluation of individual studies. Study size and duration:
The study (sample) size is used as a measure of the weight of
the evidence. In general, large studies provide more precise
estimates. Similarly, longer-duration studies may be of better
quality and more applicable, depending on other factors.
Methodological quality: Methodological quality (internal
validity) refers to the design, conduct, and reporting of the
outcomes of a clinical study. A three-level classification of
Table 33 | Literature search yield of RCTs
Topic
Abstracts
identifieda
Studies
retrieved
Studies
data-extracted
No. of systematic
reviews
No. of summary
tablesb
No. of evidence
profilesb
Total 13,516 418 94 12 72 18
RCTs, randomized controlled trials.
aAll topics and all study designs combined.
bAvailable at: www.kdigo.org/clinical_practice_guidelines/GN.php.
Table 34 |Hierarchy of outcomes
Hierarchya Outcomesb
Critical
importance
Mortality, ESRD, CKD 5, RRT
High
importance
Progression of CKD, Disease remission, Protocol-driven
additional treatment of GN, Disease relapse, Quality of
life
Moderate
importance
Partial disease remission, Proteinuria
CKD, chronic kidney disease; ESRD, end-stage renal disease; GN, glomerulonephritis;
RRT, renal replacement therapy.
aOutcomes of lesser importance are excluded from review.
bThis categorization was the consensus of the Work Group for the purposes of this
GN guideline only. The lists are not meant to reflect outcome ranking for other areas
of kidney disease management. The Work Group acknowledges that not all
clinicians, patients or families, or societies would rank all outcomes the same.
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study quality was used (Table 35). Given the potential
differences in quality of a study for its primary and other
outcomes, the methodological quality was assessed for each
outcome. Variations of this system have been used in most
KDOQI and all KDIGO guidelines, and have been recom-
mended for the US Agency for Healthcare Research and
Quality Evidence-based Practice Center program (http://
effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethods
Guide.pdf). Each study was given an overall quality grade.
Each reported outcome was then evaluated and given an
individual quality grade depending on reporting and
methodological issues specific to that outcome. However,
the quality grade of an individual outcome could not exceed
the quality grade for the overall study.
Results: The results data for each outcome of interest were
extracted including baseline values (when relevant), final
values (or number of events), and net differences (between
interventions). These included net change in values, RR, OR,
HR, and risk difference, as reported by the studies. The CI
values of the net differences and their statistical significance
were also extracted. When necessary, for categorical out-
comes, RR and their 95% CI were calculated based on
available data. The calculated data were distinguished from
the reported data in the summary tables.
Evidence profiles. Evidence profiles were constructed by
the ERT and reviewed and confirmed with the Work Group
members. These profiles serve to make transparent to the
reader the thinking process of the Work Group in system-
atically combining evidence and judgments. Each evidence
profile was reviewed by Work Group members. Decisions
were based on facts and findings from the primary studies
listed in corresponding summary tables, as well as selected
existing systematic reviews, and judgments of the Work
Group. Judgments about the quality, consistency, and
directness of evidence were often complex, as were judgments
about the importance of an outcome or the summary of
effects sizes. The evidence profiles provided a structured
transparent approach to grading, rather than a rigorous
method of quantitatively summing up grades.
Evidence profiles were constructed for research questions
addressed by at least two studies. When the body of evidence
for a particular comparison of interest consisted of only one
study, either an RCT or a systematic review, the summary
table provides the final level of synthesis.
Grading the quality of evidence and the strength of a
recommendation. A structured approach, based on
GRADE,759–761 and facilitated by the use of evidence profiles,
was used in order to grade the quality of the overall evidence
and the strength of recommendations. For each topic, the
discussion on grading of the quality of the evidence was led
by the ERT, and the discussion regarding the strength of the
recommendations was led by the Work Group Co-Chairs.
The ‘‘strength of a recommendation’’ indicates the extent to
which one can be confident that adherence to the
recommendation will do more good than harm. The ‘‘quality
of a body of evidence’’ refers to the extent to which our
confidence in an estimate of effect is sufficient to support a
particular recommendation.760
Grading the quality of evidence for each outcome: Following
the GRADE method, the quality of a body of evidence
pertaining to a particular outcome of interest was initially
categorized based on study design. For questions of
interventions, the initial quality grade was ‘‘High’’ when
the body of evidence consisted of RCTs. In theory, the
initial grade would have been ‘‘Low’’ if the evidence consisted
of observational studies or ‘‘Very Low’’ if it consisted
of studies of other study designs; however, the quality of
bodies of evidence was formally determined only for topics
where we performed systematic reviews of RCTs. The grade
for the quality of evidence for each intervention/outcome
pair was decreased if there were serious limitations to the
methodological quality of the aggregate of studies, if
there were important inconsistencies in the results across
studies, if there was uncertainty about the directness of
evidence including limited applicability of the findings to
the population of interest, if the data were imprecise (a low
event rate [0 or 1 event] in either arm or CI spanning a
range o0.5 to 42.0) or sparse (only one study or total
No100), or if there was thought to be a high likelihood of
bias. The final grade for the quality of the evidence for an
intervention/outcome pair could be one of the following
four grades: ‘‘High’’, ‘‘Moderate’’, ‘‘Low’’, or ‘‘Very Low’’
(Table 36). The quality of grading for topics relying on
systematic reviews are based on quality items recorded in the
systematic review.
Grading the overall quality of evidence: The quality of the
overall body of evidence was then determined based on the
quality grades for all outcomes of interest, taking into
account explicit judgments about the relative importance of
each outcome, weighting critical outcomes more than high or
moderate. The resulting four final categories for the quality
of overall evidence were: ‘‘A’’, ‘‘B’’, ‘‘C’’ or ‘‘D’’ (Table 37). This
evidence grade is indicated within each recommendation.
Assessment of the net health benefit across all important
clinical outcomes: The net health benefit was determined
based on the anticipated balance of benefits and harm across
all clinically important outcomes. The assessment of net
medical benefit was affected by the judgment of the Work
Group. The assessment of net health benefit is summarized in
Table 38.
Table 35 | Classification of study quality
Good
quality:
Low risk of bias and no obvious reporting errors, complete
reporting of data. Must be prospective. If study of
intervention, must be RCT.
Fair
quality:
Moderate risk of bias, but problems with study/paper are
unlikely to cause major bias. If study of intervention, must be
prospective.
Poor
quality:
High risk of bias or cannot exclude possible significant biases.
Poor methods, incomplete data, reporting errors. Prospective
or retrospective.
RCT, randomized controlled trial.
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Grading the strength of the recommendations: The strength
of a recommendation is graded as Level 1 or Level 2. Table 39
shows the KDIGO nomenclature for grading the strength of a
recommendation, and the implications of each level for
patients, clinicians, and policy-makers. Recommendations
can be for or against doing something. Table 40 shows that
the strength of a recommendation is determined not just by
the quality of the evidence, but also by other—often
complex—judgments regarding the size of the net medical
benefit, values, and preferences, and costs. Formal decision
analyses including cost analysis were not conducted.
Ungraded statements: This category was designed to allow
the Work Group to issue general advice. Typically an
ungraded statement meets the following criteria: it provides
guidance based on common sense; it provides reminders of
the obvious; it is not sufficiently specific to allow application
of evidence to the issue and, therefore, it is not based on
systematic evidence review. Common examples include
recommendations about frequency of testing, referral to
specialists, and routine medical care. We strove to minimize
the use of ungraded recommendations.
This grading scheme with two levels for the strength of a
recommendation together with four levels of grading the
quality of the evidence, and the option of an ungraded
statement for general guidance, was adopted by the KDIGO
Board in December 2008. The Work Group took the primary
role of writing the recommendations and rationale state-
ments, and retained final responsibility for the content of the
guideline statements and the accompanying narrative. The
ERT reviewed draft recommendations and grades for
consistency with the conclusions of the evidence review.
Format for recommendations. Each section contains one
or more specific recommendations. Within each recommen-
dation, the strength of recommendation is indicated as level 1
or level 2, and the quality of the supporting evidence is
shown as A, B, C, or D. These are followed by a brief
background with relevant definitions of terms, then the
Table 36 | GRADE system for grading quality of evidence
Step 1: Starting grade for
quality of evidence based on
study design Step 2: Reduce grade Step 3: Raise grade
Final grade for quality of evidence and
definition
Randomized trials =High Study quality
–1 level if serious limitations
–2 levels if very serious limitations
Strength of association
+1 level if stronga, no
plausible confounders
+2 levels if very strongb,
no major threats to validity
High= Further research is unlikely to
change confidence in the estimate of the
effect
Observational study = Low Consistency
–1 level if important inconsistency
Directness
–1 level if some uncertainty
–2 levels if major uncertainty
Other
+1 level if evidence of a
dose-response gradient
+1 level if all residual
plausible confounders
would have reduced the
observed effect
Moderate= Further research is likely to
have an important impact on confidence
in the estimate of effect, and may change
the estimate
Low=Further research is very likely to have
an important impact on confidence in the
estimate, and may change the estimate
Very Low=Any estimate of effect is very
uncertain
Any other evidence= Very
Low
Other
–1 level if sparse or imprecise datac
–1 level if high probability of
reporting bias
GRADE, Grading of Recommendations Assessment, Development, and Evaluation.
aStrong evidence of association is defined as ‘‘significant relative risk of42 (o0.5)’’ based on consistent evidence from two or more observational studies, with no plausible
confounders.
bVery strong evidence of association is defined as ‘‘significant relative risk of 45 (o0.2)’’ based on direct evidence with no major threats to validity.
cSparse if there is only one study or if total No100. Imprecise if there is a low event rate (0 or 1 event) in either arm or confidence interval spanning a rangeo0.5 to42.0.
Adapted by permission from Macmillan Publishers Ltd: Kidney International. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical
practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058–2065761; accessed http://
www.nature.com/ki/journal/v70/n12/pdf/5001875a.pdf.
Table 37 | Final grade for overall quality of evidence
Grade
Quality of
evidence Meaning
A High We are confident that the true effect lies close
to that of the estimate of the effect.
B Moderate The true effect is likely to be close to the
estimate of the effect, but there is a possibility
that it is substantially different.
C Low The true effect may be substantially different
from the estimate of the effect.
D Very Low The estimate of effect is very uncertain, and often
will be far from the truth.
Table 38 | Balance of benefits and harm
When there was evidence to determine the balance of medical benefits
and harm of an intervention to a patient, conclusions were categorized as
follows:
K Net benefits = the intervention clearly does more good than harm
K Trade-offs = there are important trade-offs between the benefits
and harm
K Uncertain trade-offs = it is not clear whether the intervention does
more good than harm
K No net benefits = the intervention clearly does not do more good
than harm
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rationale starting with a ‘‘chain of logic’’, which consists of
declarative sentences summarizing the key points of the
evidence base, and the judgments supporting the recom-
mendation. This is followed by a narrative in support of the
rationale. In relevant sections, research recommendations
suggest future research to resolve current uncertainties.
Limitations of Approach
While the literature searches were intended to be compre-
hensive, they were not exhaustive. MEDLINE and various
Cochrane databases were the only databases searched. Hand
searches of journals were not performed, and review articles
and textbook chapters were not systematically searched.
However, important studies known to the domain experts
that were missed by the electronic literature searches were
added to retrieved articles and reviewed by the Work Group.
Not all topics and subtopics covered by these guidelines could
be systematically reviewed. Decisions to restrict the topics
were made to focus the systematic reviews on those topics
where existing evidence was thought to be likely to provide
support for the guidelines. Although nonrandomized studies
were reviewed, the majority of the ERT and Work Group
resources were devoted to review of the randomized trials,
since these were deemed to be most likely to provide
data to support level 1 recommendations with very high- or
high- (A or B) quality evidence. Where randomized trials
were lacking, it was deemed to be sufficiently unlikely that
studies previously unknown to the Work Group would result
in higher-quality level 1 recommendations.
Review of the Guideline Development Process
Several tools and checklists have been developed to assess the
quality of the methodological process for systematic review
and guideline development. These include the Appraisal of
Guidelines for Research and Evaluation (AGREE) criteria,762
the Conference on Guideline Standardization (COGS) check-
list,763 and and the Institute of Medicine’s recent Standards
for Systematic Reviews764 and Clinical Practice Guidelines We
Can Trust.765 Online Appendices 2 and 3 show the COGS
criteria that correspond to the AGREE checklist and the
Institute of Medicine standards, and how each one of them is
addressed in this guideline.
SUPPLEMENTARY MATERIAL
Appendix 1: Online search strategies.
Appendix 2: The Conference on Guideline Standardization (COGS)
checklist for reporting clinical practice guidelines.
Appendix 3: Concurrence with Institute of Medicine standards for
systematic reviews and for guidelines.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/GN.php
Table 39 | KDIGO nomenclature and description for grading recommendations
Gradea
Implications
Patients Clinicians Policy
Level 1
‘‘We recommend’’
Most people in your situation
would want the recommended
course of action and only a small
proportion would not.
Most patients should receive the
recommended course of action.
The recommendation can be
evaluated as a candidate for
developing a policy or a
performance measure.
Level 2
‘‘We suggest’’
The majority of people in your
situation would want the
recommended course of action,
but many would not.
Different choices will be appropriate for
different patients. Each patient needs help to
arrive at a management decision consistent
with her or his values and preferences.
The recommendation is likely to
require substantial debate and
involvement of stakeholders before
policy can be determined.
aThe additional category ‘‘Not Graded’’ was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations
are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.
Table 40 | Determinants of strength of recommendation
Factor Comment
Balance between desirable
and undesirable effects
The larger the difference between the desirable and undesirable effects, the more likely a strong recommendation
is warranted. The narrower the gradient, the more likely a weak recommendation is warranted.
Quality of the evidence The higher the quality of evidence, the more likely a strong recommendation is warranted.
Values and preferences The more variability in values and preferences, or more uncertainty in values and preferences, the more likely
a weak recommendation is warranted.
Costs (resource allocation) The higher the costs of an intervention—that is, the more resources consumed—the less likely a strong
recommendation is warranted.
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